For years, veterinarians have relied on a familiar formula to tackle obesity in companion animals: reduce food intake, increase activity and persuade owners to stick to long-term weight management plans. While those measures remain the foundation of treatment, the rapid success of GLP-1 weight-loss medicines in human healthcare is beginning to influence veterinary medicine. Experimental therapies designed specifically for cats are now entering clinical trials, signalling that obesity treatment for pets could eventually move beyond nutrition and exercise into pharmaceutical care. The development reflects a broader transformation across the global pet industry, where healthcare, biotechnology and preventive medicine are increasingly converging as owners spend more on extending the healthy lives of their animals. 

The shift is still at an early stage. There are currently no approved GLP-1 weight-loss medicines for cats or dogs, and veterinary specialists continue to emphasise that diet management remains the first line of treatment. However, two American biotechnology companies are conducting clinical trials of obesity therapies for cats, highlighting growing confidence that medicines modelled on successful human treatments could eventually become part of veterinary practice. These developments are emerging against the backdrop of rising pet obesity rates and expanding demand for premium animal healthcare. 

Rising pet obesity is creating demand for new treatments

Obesity has become one of the most common health challenges affecting companion animals, particularly in developed countries where pets increasingly share the lifestyles of their owners.

Veterinary organisations estimate that well over half of domestic cats and dogs examined in the United States are overweight or obese. Excess body weight contributes to arthritis, diabetes, cardiovascular problems, reduced mobility and shorter life expectancy, making obesity far more than a cosmetic concern. As pets live longer and owners seek higher standards of veterinary care, managing chronic conditions has become an increasingly important part of animal healthcare. 

Cats present a particularly difficult challenge. Unlike dogs, they cannot simply be exercised through longer walks, and many resist dietary changes or consume food intended for other pets in multi-animal households. Owners often struggle to maintain consistent calorie restrictions, especially when indoor cats spend much of their lives with limited opportunities for physical activity.

These practical limitations explain why pharmaceutical approaches are attracting growing interest. Rather than replacing proper nutrition, medicines could eventually provide veterinarians with an additional option for animals whose weight cannot be adequately controlled through conventional methods alone.

Human medical breakthroughs are influencing veterinary innovation

The rapid expansion of GLP-1 medicines in human healthcare has fundamentally changed how obesity is treated, encouraging researchers to explore whether similar biological mechanisms could benefit animals.

Companies including Akston Biosciences and OKAVA Pharmaceuticals are testing different approaches for overweight cats. Akston is evaluating a once-weekly injectable therapy through research conducted with Cornell University, while OKAVA is developing a long-acting implant designed to release medication continuously for several months after a single veterinary procedure. Both products remain experimental and must demonstrate safety and effectiveness before regulators consider approval. 

Unlike human medicines such as Ozempic or Wegovy, these therapies are specifically designed for veterinary use. Researchers caution that human GLP-1 drugs should not be used in pets because dosing, metabolism and safety profiles differ significantly between species. The current studies therefore represent an effort to develop animal-specific treatments rather than simply adapting existing human medicines.

If successful, the trials could establish the first entirely new class of obesity medicines for companion animals in many years, opening opportunities for broader veterinary pharmaceutical development.

The pet industry is shifting from nutrition to healthcare

The emergence of obesity medicines reflects a much larger structural change taking place throughout the global pet economy.

For many years, premium pet food represented the industry’s primary growth driver. Manufacturers competed by offering higher-quality ingredients, specialised diets and premium branding. Increasingly, however, consumer spending is expanding into diagnostics, prescription medicines, health monitoring, supplements and preventive care.

Industry analysts describe this evolution as a transition from premium nutrition toward comprehensive healthcare. Instead of viewing food as the only solution, pet owners are increasingly willing to invest in integrated health programmes that combine veterinary advice, prescription diets, medical monitoring and potentially pharmaceutical interventions.

Large companies have already begun adapting to this changing landscape. Nestlé Purina continues investing in digestive health, healthy ageing and longevity-focused nutrition, while veterinary pharmaceutical companies are expanding therapeutic products targeting chronic conditions. Online retailers and veterinary service providers are also broadening their offerings through pharmacy subscriptions, telemedicine and integrated veterinary clinics.

This convergence means that future obesity management may combine specialised nutrition, diagnostics, behavioural guidance and medication rather than relying on a single intervention.

Longevity is becoming the industry’s next growth theme

The commercial interest surrounding pet obesity extends beyond weight loss itself.

As owners increasingly regard pets as family members, spending priorities are shifting toward extending healthy lifespan rather than simply treating illness after it develops. Advances in nutrition, early disease detection and preventive medicine are encouraging companies to develop products aimed at maintaining long-term health rather than responding only to acute medical conditions.

Obesity sits at the centre of this trend because excess weight contributes to numerous chronic diseases affecting ageing pets. Successfully managing body weight can reduce pressure on joints, improve metabolic health and potentially delay conditions requiring expensive long-term treatment.

Consequently, weight management medicines are increasingly viewed as one element within a broader longevity strategy that also includes functional nutrition, supplements, genetic testing and continuous veterinary monitoring. Companies investing in this ecosystem expect demand to grow as owners seek proactive approaches to keeping pets healthier for longer.

Commercial opportunities remain balanced by practical limitations

Despite growing enthusiasm, significant obstacles remain before GLP-1 therapies become routine veterinary treatments.

The most immediate challenge is regulatory approval. Both current feline programmes remain in clinical testing, meaning their long-term safety, effectiveness and commercial viability have yet to be demonstrated. Veterinary regulators will require robust evidence before approving widespread clinical use.

Cost also represents an important consideration. Unlike human healthcare systems, veterinary treatment is frequently paid directly by owners rather than public or private insurance. Even if medicines prove clinically successful, widespread adoption will depend heavily on affordability.

Veterinary specialists also caution against assuming that pet obesity medicines will replicate the extraordinary commercial success achieved by human GLP-1 drugs. Animal healthcare operates under different economic conditions, with owners making highly individual decisions based on treatment costs, perceived benefits and veterinary recommendations.

Consequently, prescription weight-loss medicines may initially serve as specialised treatments for difficult cases rather than becoming universal solutions for overweight pets.

Veterinary medicine is entering a new phase of preventive care

The development of obesity medicines illustrates how veterinary medicine is becoming increasingly sophisticated as scientific advances in human healthcare begin influencing animal treatment.

Whether current GLP-1 therapies ultimately succeed or not, the research itself signals an important shift. Obesity is no longer being viewed solely as a behavioural or nutritional issue but increasingly as a chronic medical condition requiring multiple treatment options tailored to individual animals.

At the same time, the industry’s response demonstrates that pharmaceutical innovation will not replace traditional weight management strategies. Nutrition, controlled feeding, physical activity and regular veterinary supervision will remain fundamental to preventing obesity, while medicines—if approved—are likely to complement rather than substitute these established approaches.

The growing intersection of biotechnology, preventive medicine and premium pet care suggests that future veterinary practice will become increasingly personalised. As research continues and owners place greater value on extending healthy lifespan, the treatment of obesity may become one of the clearest examples of how companion animal healthcare is evolving from routine care into a more comprehensive medical discipline.

(Adapted from CNBC.com)